Zimmer Biomet Holdings Inc (ZBH) : Stock Yards Bank Trust Co scooped up 9,743 additional shares in Zimmer Biomet Holdings Inc during the most recent quarter end , according to a recent disclosure to the SEC on Apr 5, 2016. The investment management firm now holds a total of 64,764 shares of Zimmer Biomet Holdings Inc which is valued at $7.1 Million.Zimmer Biomet Holdings Inc makes up approximately 1.02% of Stock Yards Bank Trust Co’s portfolio.
Other Hedge Funds, Including , Beacon Financial Group reduced its stake in ZBH by selling 74 shares or 1.25% in the most recent quarter. The Hedge Fund company now holds 5,853 shares of ZBH which is valued at $628,437. Zimmer Biomet Holdings Inc makes up approx 0.14% of Beacon Financial Group’s portfolio.
On the company’s financial health, Zimmer Biomet Holdings Inc reported $2.09 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Jan 28, 2016. Analyst had a consensus of $2.04. The company had revenue of $1933.60 million for the quarter, compared to analysts expectations of $1954.47 million. The company’s revenue was up 58.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.78 EPS.
Many Wall Street Analysts have commented on Zimmer Biomet Holdings Inc. Company shares were Reiterated by RBC Capital Mkts on Apr 15, 2016 to “Outperform”, Firm has raised the Price Target to $ 132 from a previous price target of $120 .Zimmer Biomet Holdings Inc was Initiated by Nomura to “Buy” on Mar 17, 2016. Zimmer Biomet Holdings Inc was Downgraded by Argus to ” Hold” on Mar 4, 2016.
Zimmer Biomet Holdings Inc opened for trading at $109.06 and hit $109.71 on the upside on Monday, eventually ending the session at $109.3, with a gain of 0.31% or 0.34 points. The heightened volatility saw the trading volume jump to 13,96,002 shares. Company has a market cap of $21,733 M.
Zimmer Biomet Holdings Inc. formerly Zimmer Holdings Inc. is a musculoskeletal healthcare company. The Company designs manufactures and markets orthopedic reconstructive products; sports medicine biologics extremities and trauma products; spine bone healing craniomaxillofacial and thoracic products; dental implants and related surgical products. The Company manages its operations through three geographic segments: the Americas comprising principally of the United States and includes other North Central and South American markets; Europe comprising principally of Europe and includes the Middle East and African markets; and Asia Pacific comprising primarily of Japan and includes other Asian and Pacific markets. The Company markets and sells products through three channels: direct to healthcare institutions such as hospitals or direct channel accounts; through stocking distributors and healthcare dealers and directly to dental practices and dental laboratories.